Drug Trial Radar · NCT07857616
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
424
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Oct 2028
Study completion Oct 2029
Sponsor
- Lead sponsor
- SystImmune Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
Conditions
- Locally Advanced /Metastatic Solid Tumors
- Locally Advanced / Metastatic Solid Tumors
- Metastatic Solid Cancers
- Non Small Cell Lung Cancer
- Lung Cancer
- Melanoma
- Ovarian
- NSCLC
Interventions
SI-B036Drug
SI-B036 will be administered on Day 1 by intravenous (IV) infusion every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with Dose-Limiting ToxicitiesTime frame: 24 months
- Participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs)Time frame: 24 months
- Participants with abnormal physical examination findingsTime frame: 24 months
- Participants with abnormal lab resultsTime frame: 24 months
- Participants with abnormal ECG readingTime frame: 24 months
- To determine the maximum tolerated dose (MTD) if reached or minimum safe and pharmacologically effective dose (MSED).Time frame: 24 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut · Not yet recruiting
Florida Cancer Specialists Lake Nona
Orlando, Florida · Recruiting
Florida Cancer Specialists Sarasota
Sarasota, Florida · Recruiting
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma · Not yet recruiting
Sarah Cannon Research Institute - Oncology Partners
Nashville, Tennessee · Recruiting
Mary Crowley Cancer Research
Dallas, Texas · Recruiting
MD Anderson
Houston, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.